_id
69105677ccc777a4e85d5626
Ticker
CTKB
Name
Cytek Biosciences Inc
Exchange
NASDAQ
Address
47215 Lakeview Boulevard, Fremont, CA, United States, 94538
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://cytekbio.com
Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Last Close
4.97
Volume
658393
Current Price
4.86
Change
-2.213279678068399
Last Updated
2025-11-29T11:57:26.119Z
Image
-
Ipo Date
2021-07-23T00:00:00.000Z
Market Cap
722436288
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9880285714285713
Sentiment Sources
7
Rating
3.3333
Target Price
5.25
Strong Buy
1
Buy
1
Hold
3
Sell
1
Strong Sell
0
Current Quarter
2025-09-30
Revenue
52293000
Cost Of Revenue
24742000
Gross Profit
27551000
Operating Expenses
36743000
Operating Income
-9192000
Interest Expense
494000
Pretax Income
-7769000
Net Income
-5478000
Eps
-0.0429485844995642
Dividends Per Share
-
Shares Outstanding
127864830
Income Tax Expense
-2291000
EBITDA
-4215000
Operating Margin
-17.57787849234123
Total Other Income Expense Net
1423000
Cash
93281000
Short Term Investments
168453000
Receivables
61673000
Inventories
51649000
Total Current Assets
388489000
Property Plant Equipment
29204000
Total Assets
494919000
Payables
7632000
Short Term Debt
12854000
Long Term Debt
655000
Total Liabilities
116348000
Equity
378571000
Depreciation
3060000
Change In Working Capital
-3563000
Cash From Operations
-3898000
Capital Expenditures
655000
Cash From Investing
18920000
Cash From Financing
1941000
Net Change In Cash
17811000
PE
-
PB
1.6374275756463121
ROE
-1.4470205060609502
ROA
-1.1068477872136653
FCF
-4553000
Fcf Percent
-0.08706710267148567
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
3.5
Growth Investing Score
2
Momentum Investing Score
5
Net Net Investing Score
1
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
52293000
Quarters > 0 > income Statement > cost Of Revenue
24742000
Quarters > 0 > income Statement > gross Profit
27551000
Quarters > 0 > income Statement > operating Expenses
36743000
Quarters > 0 > income Statement > operating Income
-9192000
Quarters > 0 > income Statement > interest Expense
494000
Quarters > 0 > income Statement > pretax Income
-7769000
Quarters > 0 > income Statement > net Income
-5478000
Quarters > 0 > income Statement > eps
-0.0429485844995642
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
127547859
Quarters > 0 > income Statement > income Tax Expense
-2291000
Quarters > 0 > income Statement > EBITDA
-4215000
Quarters > 0 > income Statement > operating Margin
-17.57787849234123
Quarters > 0 > income Statement > total Other Income Expense Net
1423000
Quarters > 0 > balance Sheet > cash
93281000
Quarters > 0 > balance Sheet > short Term Investments
168453000
Quarters > 0 > balance Sheet > receivables
61673000
Quarters > 0 > balance Sheet > inventories
51649000
Quarters > 0 > balance Sheet > total Current Assets
388489000
Quarters > 0 > balance Sheet > property Plant Equipment
29204000
Quarters > 0 > balance Sheet > total Assets
494919000
Quarters > 0 > balance Sheet > payables
7632000
Quarters > 0 > balance Sheet > short Term Debt
12854000
Quarters > 0 > balance Sheet > long Term Debt
655000
Quarters > 0 > balance Sheet > total Liabilities
116348000
Quarters > 0 > balance Sheet > equity
378571000
Quarters > 0 > cash Flow > net Income
-5478000
Quarters > 0 > cash Flow > depreciation
3060000
Quarters > 0 > cash Flow > change In Working Capital
-3563000
Quarters > 0 > cash Flow > cash From Operations
-3898000
Quarters > 0 > cash Flow > capital Expenditures
655000
Quarters > 0 > cash Flow > cash From Investing
18920000
Quarters > 0 > cash Flow > cash From Financing
1941000
Quarters > 0 > cash Flow > net Change In Cash
17811000
Quarters > 0 > ratios > PE
-0.0429485844995642
Quarters > 0 > ratios > PB
1.6374275756463121
Quarters > 0 > ratios > ROE
-1.4470205060609502
Quarters > 0 > ratios > ROA
-1.1068477872136653
Quarters > 0 > ratios > FCF
-4553000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-0.08706710267148567
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
45602000
Quarters > 1 > income Statement > cost Of Revenue
21735000
Quarters > 1 > income Statement > gross Profit
23867000
Quarters > 1 > income Statement > operating Expenses
34491000
Quarters > 1 > income Statement > operating Income
-10624000
Quarters > 1 > income Statement > interest Expense
414000
Quarters > 1 > income Statement > pretax Income
-6775000
Quarters > 1 > income Statement > net Income
-5583000
Quarters > 1 > income Statement > eps
-0.043983487481683396
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
126934000
Quarters > 1 > income Statement > income Tax Expense
-1192000
Quarters > 1 > income Statement > EBITDA
-3373000
Quarters > 1 > income Statement > operating Margin
-23.29722380597342
Quarters > 1 > income Statement > total Other Income Expense Net
3849000
Quarters > 1 > balance Sheet > cash
75470000
Quarters > 1 > balance Sheet > short Term Investments
186552000
Quarters > 1 > balance Sheet > receivables
56668000
Quarters > 1 > balance Sheet > inventories
49487000
Quarters > 1 > balance Sheet > total Current Assets
382825000
Quarters > 1 > balance Sheet > property Plant Equipment
34739000
Quarters > 1 > balance Sheet > total Assets
493320000
Quarters > 1 > balance Sheet > payables
6853000
Quarters > 1 > balance Sheet > short Term Debt
8769000
Quarters > 1 > balance Sheet > long Term Debt
791000
Quarters > 1 > balance Sheet > total Liabilities
115763000
Quarters > 1 > balance Sheet > equity
377557000
Quarters > 1 > cash Flow > net Income
-5583000
Quarters > 1 > cash Flow > depreciation
2988000
Quarters > 1 > cash Flow > change In Working Capital
-785000
Quarters > 1 > cash Flow > cash From Operations
108000
Quarters > 1 > cash Flow > capital Expenditures
1577000
Quarters > 1 > cash Flow > cash From Investing
-16413000
Quarters > 1 > cash Flow > cash From Financing
-2602000
Quarters > 1 > cash Flow > net Change In Cash
-19829000
Quarters > 1 > ratios > PE
-0.043983487481683396
Quarters > 1 > ratios > PB
1.6339234605635706
Quarters > 1 > ratios > ROE
-1.4787171208585723
Quarters > 1 > ratios > ROA
-1.1317197762101678
Quarters > 1 > ratios > FCF
-1469000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.032213499407920704
Quarters > 1 > health Score
36
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
41457000
Quarters > 2 > income Statement > cost Of Revenue
21300000
Quarters > 2 > income Statement > gross Profit
20157000
Quarters > 2 > income Statement > operating Expenses
35132000
Quarters > 2 > income Statement > operating Income
-14975000
Quarters > 2 > income Statement > interest Expense
291000
Quarters > 2 > income Statement > pretax Income
-11266000
Quarters > 2 > income Statement > net Income
-11402000
Quarters > 2 > income Statement > eps
-0.08884283031658342
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
128339000
Quarters > 2 > income Statement > income Tax Expense
136000
Quarters > 2 > income Statement > EBITDA
-8091000
Quarters > 2 > income Statement > operating Margin
-36.1217647200714
Quarters > 2 > income Statement > total Other Income Expense Net
3709000
Quarters > 2 > balance Sheet > cash
95298000
Quarters > 2 > balance Sheet > short Term Investments
170314000
Quarters > 2 > balance Sheet > receivables
55207000
Quarters > 2 > balance Sheet > inventories
45347000
Quarters > 2 > balance Sheet > total Current Assets
380501000
Quarters > 2 > balance Sheet > property Plant Equipment
27702000
Quarters > 2 > balance Sheet > total Assets
482596000
Quarters > 2 > balance Sheet > payables
6247000
Quarters > 2 > balance Sheet > short Term Debt
7531000
Quarters > 2 > balance Sheet > long Term Debt
918000
Quarters > 2 > balance Sheet > total Liabilities
102973000
Quarters > 2 > balance Sheet > equity
379623000
Quarters > 2 > cash Flow > net Income
-11402000
Quarters > 2 > cash Flow > depreciation
2884000
Quarters > 2 > cash Flow > change In Working Capital
3029000
Quarters > 2 > cash Flow > cash From Operations
-125000
Quarters > 2 > cash Flow > capital Expenditures
851000
Quarters > 2 > cash Flow > cash From Investing
9452000
Quarters > 2 > cash Flow > cash From Financing
-11545000
Quarters > 2 > cash Flow > net Change In Cash
-3446000
Quarters > 2 > ratios > PE
-0.08884283031658342
Quarters > 2 > ratios > PB
1.6430183102709794
Quarters > 2 > ratios > ROE
-3.0035061100091407
Quarters > 2 > ratios > ROA
-2.3626387288746695
Quarters > 2 > ratios > FCF
-976000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.023542465687338688
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
57476000
Quarters > 3 > income Statement > cost Of Revenue
23824000
Quarters > 3 > income Statement > gross Profit
33652000
Quarters > 3 > income Statement > operating Expenses
30666000
Quarters > 3 > income Statement > operating Income
2986000
Quarters > 3 > income Statement > interest Expense
694000
Quarters > 3 > income Statement > pretax Income
10323000
Quarters > 3 > income Statement > net Income
9643000
Quarters > 3 > income Statement > eps
0.07463281417773636
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
129205901
Quarters > 3 > income Statement > income Tax Expense
680000
Quarters > 3 > income Statement > EBITDA
-2453000
Quarters > 3 > income Statement > operating Margin
5.195211914538242
Quarters > 3 > income Statement > total Other Income Expense Net
7337000
Quarters > 3 > balance Sheet > cash
98716000
Quarters > 3 > balance Sheet > short Term Investments
179145000
Quarters > 3 > balance Sheet > receivables
60588000
Quarters > 3 > balance Sheet > inventories
43893000
Quarters > 3 > balance Sheet > total Current Assets
396446000
Quarters > 3 > balance Sheet > property Plant Equipment
28130000
Quarters > 3 > balance Sheet > total Assets
499500000
Quarters > 3 > balance Sheet > payables
5529000
Quarters > 3 > balance Sheet > short Term Debt
8414000
Quarters > 3 > balance Sheet > long Term Debt
1050000
Quarters > 3 > balance Sheet > total Liabilities
103763000
Quarters > 3 > balance Sheet > equity
395737000
Quarters > 3 > cash Flow > net Income
9643000
Quarters > 3 > cash Flow > depreciation
2741000
Quarters > 3 > cash Flow > change In Working Capital
-5500000
Quarters > 3 > cash Flow > cash From Operations
1997000
Quarters > 3 > cash Flow > capital Expenditures
903000
Quarters > 3 > cash Flow > cash From Investing
-63433000
Quarters > 3 > cash Flow > cash From Financing
-3640000
Quarters > 3 > cash Flow > net Change In Cash
-63558000
Quarters > 3 > ratios > PE
0.07463281417773636
Quarters > 3 > ratios > PB
1.5867626197702012
Quarters > 3 > ratios > ROE
2.4367193363269037
Quarters > 3 > ratios > ROA
1.9305305305305303
Quarters > 3 > ratios > FCF
1094000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
0.019034031595796506
Quarters > 3 > health Score
54
Valuation > metrics > PE
-0.0429485844995642
Valuation > metrics > PB
1.6374275756463121
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-1.4470205060609502
Profitability > metrics > ROA
-1.4100785350421763
Profitability > metrics > Net Margin
-0.10475589467041478
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3073346875487029
Risk > metrics > Interest Coverage
-18.60728744939271
Risk > final Score
-14
Risk > verdict
High
Liquidity > metrics > Current Ratio
18.96363370106414
Liquidity > metrics > Quick Ratio
16.4424485014156
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
100
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
37
Prev Risks > 0
-43
Prev Risks > 1
-146
Prev Risks > 2
77
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:22:19.019Z
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABrown Capital Management LLC Has $24.17 Million Stock Position in Cytek Biosciences, Inc. $CTKB MarketBeat
Read more →Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $7.5 富途资讯
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
HOLD
Target Price:
$5.25
Analyst Picks
Strong Buy
1
Buy
1
Hold
3
Sell
1
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 73.05% of the total shares of Cytek Biosciences Inc
1.
BlackRock Inc(13.3902%)
since
2025/06/30
2.
Vanguard Group Inc(6.1035%)
since
2025/06/30
3.
Brown Capital Management, LLC(5.5886%)
since
2025/06/30
4.
Hillhouse Capital Advisors, Ltd.(5.2325%)
since
2025/06/30
5.
iShares Core S&P Small-Cap ETF(4.8256%)
since
2025/08/31
6.
Topline Capital Management LLC(4.1119%)
since
2025/06/30
7.
State Street Corp(3.2806%)
since
2025/06/30
8.
Dimensional Fund Advisors, Inc.(2.7155%)
since
2025/06/30
9.
Vanguard Total Stock Mkt Idx Inv(2.6894%)
since
2025/07/31
10.
iShares Russell 2000 ETF(2.2245%)
since
2025/08/31
11.
Geode Capital Management, LLC(2.1455%)
since
2025/06/30
12.
New York State Common Retirement Fund(1.6415%)
since
2025/06/30
13.
Brown Capital Mgmt Small Co Inv(1.6352%)
since
2025/03/31
14.
Royce & Associates, LP(1.0924%)
since
2025/06/30
15.
AQR Capital Management LLC(0.9734%)
since
2025/06/30
16.
Fidelity Small Cap Index(0.9305%)
since
2025/06/30
17.
Morgan Stanley - Brokerage Accounts(0.904%)
since
2025/06/30
18.
Vanguard Institutional Extnd Mkt Idx Tr(0.8872%)
since
2025/07/31
19.
Northern Trust Corp(0.8615%)
since
2025/06/30
20.
Renaissance Technologies Corp(0.8356%)
since
2025/06/30
21.
iShares Russell 2000 Value ETF(0.8247%)
since
2025/08/31
22.
Goldman Sachs Group Inc(0.799%)
since
2025/06/30
23.
iShares S&P Small-Cap 600 Value ETF(0.7527%)
since
2025/08/31
24.
Millennium Management LLC(0.7269%)
since
2025/06/30
25.
Charles Schwab Investment Management Inc(0.715%)
since
2025/06/30
26.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.713%)
since
2025/08/29
27.
Jacobs Levy Equity Management, Inc.(0.6982%)
since
2025/06/30
28.
Royce Micro Cap Trust(0.6605%)
since
2025/06/30
29.
Bank of New York Mellon Corp(0.5501%)
since
2025/06/30
30.
iShares Biotechnology ETF(0.5408%)
since
2025/08/31
31.
UBS Group AG(0.4968%)
since
2025/06/30
32.
Brown Capital Small Company(0.4705%)
since
2025/06/30
33.
Fidelity Extended Market Index(0.4435%)
since
2025/07/31
34.
Vanguard Russell 2000 ETF(0.4406%)
since
2025/07/31
35.
SPDR® S&P 600 Small Cap Value ETF(0.4343%)
since
2025/08/31
36.
Schwab US Small-Cap ETFâ„¢(0.3813%)
since
2025/08/30
37.
State St Russell Sm Cap® Indx SL Cl I(0.3437%)
since
2025/08/31
38.
DFA US Small Cap I(0.3358%)
since
2025/07/31
39.
DFA US Micro Cap I(0.3356%)
since
2025/07/31
40.
Principal SmallCap S&P 600 Idx SP(0.3182%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.